• Donate
  • Contact
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
  • About Pompe
    • Diagnosing Pompe
    • Talk Pompe
    • Webinars
  • Blog
  • Resources
    • Pompe – How to
    • Links
    • Connections
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
  • About Pompe Disease
  • Diagnosing Pompe Disease
    • Talk Pompe
    • Webinars
  • Blog
  • Resources
    • Pompe – How to
    • Links
    • Connections
  • Donate
  • Contact
Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

by Brad Crittenden | Feb 25, 2019 | News

Amicus Therapeutics announced today that they have received Breakthrough Therapy Designation (BTD) for their AT-GAA treatment for Pompe disease.

Recent Posts

  • Nexviazyme Meets All Endpoints in Phase 3 Study for Infantile-Onset Pompe Disease
  • First Participant Dosed in Phase 1/2 Gene Therapy Trial for Late-Onset Pompe Disease
  • First Patients Enrolled in Phase 2 Trial of SRT for Late-Onset Pompe Disease
  • Aro Biotherapeutics reports positive phase 1b results for ABX1100
  • 2025 Pompe Empowerment Workshop : Vancouver
  • Terms
  • Privacy
Copyright © 2006 -2026 Canadian Association of Pompe
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.